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 Referat / Abstract 
 
High expression levels of the gene BAALC (brain and acute leukemia, cytoplasmic) are 
associated with poor prognosis in acute myeloid leukemia (AML) patients, but the 
underlying mechanisms are not yet understood. We evaluated the prognostic 
significance of expression levels of miR-3151, a newly discovered microRNA embedded 
in intron 1 of the BAALC gene, in a cohort of 179 older (≥60 years) cytogenetically 
normal AML (CN-AML) patients, in the context of established molecular markers and 
especially with regard to the possible interplay with its host gene BAALC. In 
multivariable analyses, high miR-3151 was associated with shorter disease-free and 
overall survival (OS), while higher BAALC expression strongly predicted failure of 
complete remission attainment and OS. Patients exhibiting both high miR-3151 and 
BAALC expression had worse outcome than patients expressing low levels of either one 
of the genes or both. Next, gene - and microRNA-expression profiles associated with 
miR-3151 expression were derived using microarrays, and a pathway analysis of the 
miR-3151 associated gene signature was performed using Ingenuity software. High 
miR-3151 expressers showed downregulation of genes involved in transcriptional 
regulation, post-translational modifications and cell-cycle control. Two genes of the 
ubiquitination pathway, FBXL20 and USP40, were experimentally validated as direct 
miR-3151 targets. In summary, we identified high expression levels of the intronic miR-
3151 as a novel, independent prognosticator for poor outcome in CN-AML. Interestingly, 
miR-3151 impacted differently on outcome than its host gene BAALC; and the 
combination of both markers identified a patient subset with the poorest outcome, 
suggesting that the microRNA and its host gene contribute to clinical and prognostic 
features of CN-AML independently and through distinct mechanisms. This is the first 
example of the interplay of an intronic miR and its host gene in leukemia. Its discovery 
may have important biologic implications for future targeted treatment strategies.  
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Einführung / Introduction 
 
Acute Myeloid Leukemia (AML) is a complex disease, which is characterized by the 
uncontrolled proliferation of a leukemic clone in the bone marrow. In recent years, new 
insights into the biology have significantly improved our understanding of AML. But, 
despite this progress, the outcome of the majority of AML patients still remains poor and 
only a fraction of the patients achieves long term survival.1-3 The outcome is especially 
poor in patients aged 60 years or older, of whom only ~15% achieve a long term 
survival.1-3 
Very soon it became clear, that the cytogenetical and molecular heterogeneity may be 
the reason for the different outcomes of the patient, since each chromosomal and/or 
molecular abnormality in the leukemic clone may lead to a more or less aggressive 
disease course. Today, numerous clinical, cytogenetic and molecular variables have 
been found to be associated with AML outcome.4-16 Their discoveries raised hopes to 
better predict the individual chances of treatment response and potentially lead to more 
personalized, risk-adapted therapeutic strategies for AML patients. Among the 
prognostic markers, mutations in the (nucleolar phosphoprotein B23, numatrin) 
(NPM1)15 and CCAAT/enhancer binding protein C/EBP, alpha (CEBPA)8 genes are 
associated with favorable outcome and have been included as provisional entities in the 
World Health Organization classification of AML.17 These two mutations as well as the 
presence of internal tandem duplications of the fms-related tyrosine kinase 3 gene 
(FLT3-ITD)5 that has been associated with unfavorable outcome, have been 
incorporated into a standardized reporting system for genetic abnormalities suggested 
by an international expert panel on behalf of the European LeukemiaNet (ELN),18 and 
should be determined in every AML patient. 
In addition to the presence of gene mutations, the differential expression of specific 
genes has also been proven to be of prognostic significance in AML. Examples for 
those gene expression markers are, among others, the v-ets erythroblastosis virus E26 
oncogene homolog (avian) (ERG),19 meningioma (disrupted in balanced translocation) 1 
(MN1),16 the dominant negative helix-loop-helix protein ID1,20 and the surface marker 
CD200.7 It is important to know, that the underlying (leukemogenic) mechanisms for 
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some of these markers are known, while for others their connection to leukemia 
pathogenesis has not been discovered yet. 
Another gene, whose high expression levels have been shown to associate with poor 
prognosis in AML patients is the BAALC (brain and acute leukemia cytoplasmic) gene, 
which was identified by cDNA-based representational difference analysis in leukemia 
patients.21 The prognostic impact of BAALC expression has been most extensively 
studied in AML patients with a normal karyotype (CN-AML),19, 22-24 with high expression 
levels being associated with a lower complete remission (CR) rate, as well as shorter 
disease-free (DFS) and overall survival (OS) of the patients.19,22 Although recent data 
suggest that BAALC contributes to leukemogenesis by interfering with normal patterns 
of myeloid differentiation,23 the function of this gene and the mechanism(s) through 
which its high expression levels impact negatively on clinical outcome remain(s) 
unknown. Taking together the known published data on BAALC’s impact on outcome of 
AML patients, deciphering BAALC’s function may be of high interest to the scientific 
community. But, since multiple attempts of various study groups failed so far, new 
avenues and research approaches may have to be taken to gain more insights into the 
leukemogenic properties of the BAALC locus. 
 
MicroRNAs (miRs) are noncoding RNAs that downregulate gene expression by 
inhibiting translation or promoting mRNA degradation.26 Their targets can be various 
and may vary by tissue- and cell type; potentially providing simultaneous regulation of 
multiple genes to regulate a specific pathway. They are not only involved in such 
biological processes as cellular differentiation, proliferation and survival but also play an 
essential role in the development of solid tumors and AML.26-30 miR genes can be found 
throughout the genome, but about one third of mammalian miRs are located within 
introns of host genes,31,32 and most of them are believed to be co-expressed and 
processed from the same precursor mRNA in which they reside,33-35 while 
approximately 26% of intronic miRs have their own promoters.36,37 The functional 
relationship of miR genes and their hosts is vastly unknown. Most intronic miRs are 
thought to strengthen the function of its host gene, which may happen in a direct 
manner by targeting genes within the same cellular pathway,38,39 while other miRs have 
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been shown to silence genes which are acting antagonistic to their hosts.40 Additionally, 
it could be shown that some miRs may even be made accountable for effects which 
have been thought to be caused by their host gene and that they can be achieved 
independent of the expression of their host gene.41 
Recently, deep sequencing of melanoma42 and acute lymphoblastic leukemia samples43 
led to the discovery of a novel miR, miR-3151, which was found to be embedded in 
intron 1 of BAALC. 
We therefore hypothesized, that miR-3151 might also be aberrantly expressed in 
patients with high expression levels of its host gene BAALC and might also –
dependently or independently - impact on outcome of AML patients. Furthermore, since 
the function of BAALC is still unknown, we hypothesized that miR-3151 may either be 
the crucial partner needed for an unknown leukemogenic function of BAALC, or even be 
the element predominantly responsible for the adverse outcome of patients with high 
BAALC expression levels. Thus, miR-3151 may be a novel oncomiR. 
In our here presented study, we measured the expression levels of miR-3151 and its 
host gene BAALC in a set of 179 CN-AML patients aged 60 years and older by RT 
Real-Time PCR. To compare the prognostic impact of miR-3151 expression levels to 
the impact of other well-established molecular markers, we additionally analyzed all 
patients for the presence or absence of FLT3-ITD,5 FLT3 tyrosine kinase domain 
mutations (FLT3-TKD),6 partial tandem duplication of the myeloid/lymphoid or mixed-
lineage leukemia (trithorax homolog, Drosophila) gene (MLL-PTD),4 mutations in the 
NPM1,15 CEBPA,8 tet methylcytosine dioxygenase 2 (TET2),12 additional sex combs like 
1 (Drosophila) (ASXL1),13 DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A),10 
runt-related transcription factor 1 (RUNX1),11 Wilms tumor 1 (WT1),14 and isocitrate 
dehydrogenase 1 (NADP+), soluble (IDH1) and isocitrate dehydrogenase 2 (NADP+), 
mitochondrial (IDH2) 9 genes, and expression levels of ERG19 and MN116. 
Additionally, gene- and microRNA expression profiling was performed with the aim to 
analyze the derived gene expression signatures for enrichments of specific pathways 
and/or biologic functions. Finally, we aimed to validate two of the most important genes 
of the signature as direct targets of miR-3151, thereby giving first insights into the 











































Zusammenfassung / Conclusion 
 
Since the here presented study evolved out of the aim to better understand the biology 
and function of BAALC, three main conclusions may be drawn. 
1) We could, for the first time, demonstrate an independent prognostic impact of 
BAALC’s intronic microRNA miR-3151. In addition, we could validate the 
important prognostic impact of BAALC expression in older CN-AML patients, 
especially on the achievement of CR and OS.  
2) Both genes impacted on different outcome endpoints and showed also 
differences in their associated gene-expression signatures. Thus, neither does 
miR-3151 explain -in full - the impact of BAALC expression levels (BAALC is not 
only a meaningless cover gene), nor does BAALC account for the impact of miR-
3151 expression levels. 
3) BAALC and miR-3151 may have to be interpreted as an oncogenic locus, which 
interplays towards leukemogenesis. 
 
Within the scope of this thesis we present a study that reported miR-3151 as an 
independent prognostic factor for outcome in older patients with CN-AML. The impact of 
miR-3151 expression on survival probability was independent from other, well-
established molecular markers (eg, NPM1 mutations and FLT3-ITD) and notably also 
independent from the expression status of its host gene BAALC. Importantly, higher 
expression of miR-3151 impacted on different outcome endpoints than BAALC: The 
effect of BAALC was mainly on achievement of CR while that of miR-3151 was mainly 
on outcome- once CR had been achieved (DFS); naturally then both BAALC and miR-
3151 affected OS in these older patients. Patients with high expression levels of both 
genes were identified as the patient subset with the poorest outcome. In general, 
patients who had high expression of both miR-3151 and BAALC did worst, patients with 
low expression of both genes did best, and patients with discordant expresser status 
had intermediate outcomes.  
The publication of a standardized reporting system for genetic abnormalities suggested 
by an international expert panel on behalf of the European LeukemiaNet (ELN) enabled 
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clinicians with a tool to stratify AML patients based on both cytogenetic abnormalities 
and the presence or absence of the mutational status of the established molecular 
markers NPM1, CEBPA and FLT3-ITD. Therefore, it was important to test the impact of 
miR-3151 expression levels within those ELN Genetic Groups. Interestingly, miR-3151 
expression was able to identify a subset with an especially poor outcome within the ELN 
Intermediate-I Genetic Group. Notably, the DFS and OS rates of patients with low miR-
3151 expression levels were comparable to the survival rates of patients belonging to 
the ELN Favorable Genetic Group. In contrast, miR-3151 expression levels were 
without influence on the outcome of patients belonging to the ELN Favorable Genetic 
Group. Thus, determination of miR-3151 expression levels may be a useful tool to refine 
the risk stratification proposed in the guidelines of the ELN. But, even knowing about the 
important prognostic information which may be gained by the determination of miR-
3151 and BAALC expression levels in the pre-treatment peripheral blood of AML 
patients, it has to be kept in mind that the clinical use of those expression markers is so 
far still limited by the difficulties to standardize the methods for gene- and microRNA 
expression determination for individual patients and by the lack of absolute cut-offs to 
undoubtedly define high and low expressing patients. Once those technical difficulties 
are overcome, the usage of gene expression markers may be similar or even better 
than the one gained by the mutational analysis, since the expression markers may 
reflect the combined downstream effects of a plethora of molecular features, such as 
different gene mutations or epigenetic events. Besides the clinical observations, our aim 
was to gain first insights into the downstream biology of miR-3151-associated leukemia. 
Therefore, we performed a global gene-expression profiling in our patient cohort and 
were able to derive a distinct gene-expression signature associated with high miR-3151 
expression levels. Using ingenuity software, we next performed a detailed gene 
ontology analysis to identify genes and subsequent pathways which are enriched in 
high miR-3151 expressing patients. This gene ontology analysis revealed pathways 
regulating gene expression, cell-cycle control and post-transcriptional regulation to be 
primarily affected by high miR-3151 expression levels. As a next step, we aimed to 
validate two of the most downregulated genes of the miR-3151-associated signature as 
direct miR-3151 targets. For identification of these genes, we used a significance-based 
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algorithm. Interestingly, 2 out of the 6 genes which fulfilled our selection criteria 
belonged to the ubiquitination pathway44- which goes in line with our previous 
observation that miR-3151 impacts on post-transcriptional regulation pathways. Both 
genes, FBXL2045 and USP4046 could be validated as direct miR-3151 target genes. 
FBXL20 belongs to the F-BOX proteins and is - as a part of the SCF (Skp, Cullin, F-box 
containing) -complex - responsible for the ubiquitination and consecutive degradation of 
its target genes.45 The SCF-complex is a multiprotein complex catalyzing the 
ubiquitination of proteins destined for degradation, in which the F-box proteins (eg, 
FBXL20) contribute to the specificity of the complex, since they are the part which is 
binding to the target proteins. This protein- “capture” then allows the ubiquitin ligase (eg, 











So far, nothing is known about specific FBXL20 targets. However, the identification of 
such genes may be an interesting topic of future research to further understand the 
downstream biology of high miR-3151 expression levels and to potentially find new links 
in the complex networking of AML signaling pathways. Since we already have a 
successfully working antibody for FBXL20, which has been used for Western blotting in 
the publication, a next step may be the immunoprecipitation and consecutive mass-
spectrometric analysis to identify the proteins bound to FBXL20.  
The comparison of the miR-3151-associated gene- and microRNA-expression 
signatures with the gene- and microRNA-expression signatures previously reported to 
be associated with high expression levels of the host gene BAALC led to additional 
Figure 1. The SCF-(Skp, Cullin, F-box 
containing) complex. The F-box proteins (eg, 
FBXL20) define the specificity of the complex by 
providing the target gene sequence to bind the 
proteins destined for ubiquitination and proteasomal 
degradation. 
 
Figure adapted from: Morgan, David “Protein 
Degradation in Cell-Cycle Control”, The Cell Cycle; 
Principles of Control 2007 
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important observations. Despite the strong association of the expression levels of both 
genes, interesting differences in the differentially expressed genes in both signatures 
could be observed. While high BAALC expression was associated with high expression 
of the stemness-markers PROM1 and CD34, no such association could be observed in 
high miR-3151 expressing patients. In contrast, downregulation of the let-7 family, which 
was the key-feature of the miR-3151-associated microRNA-expression signature, has 
not been observed in high BAALC expressing patients.  
Interestingly, in one of the initial studies of BAALC, Baldus et al. suggested that high 
BAALC expression may lose its prognostic importance in patients undergoing allogeneic 
hematopoietic stem cell transplantation (HCT).22 Thus, as a pilot study, we measured 
pre-treatment BAALC and miR-3151 expression levels in a total of 75 older AML 
patients with mixed karyotypes, which underwent allogeneic HCT at the University of 
Leipzig. In these patients we also assessed the NPM1 mutation status. Similarly to the 
observations in the patients from the Cancer and Leukemia Group B (CALGB) study 
(presented study) we observed an association of high BAALC and high miR-3151 
expresser status – using a median cut for both genes to define high and low expressers 
- with NPM1 wild-type (P=0.0024 and P=0.013, respectively). Furthermore, again 
validating our findings of the CALGB patient set, we observed an association between 
high BAALC and high miR-3151 expresser status in the Leipzig patient set (P=.04). 
However, about 40% (n=30) of the patients had a discordant expresser status of the two 
genes. For a subset of the investigated Leipzig patients (n=22) follow-up data for a 
preliminary outcome analysis was available. Utilizing the Kaplan-Meier Method, we 
analyzed the OS according to the BAALC and miR-3151 expresser status. In this 
analysis, both miR-3151 and BAALC failed as a single marker to significantly separate 




















However, when following the proposal to analyze the combined effect of the 
BAALC/miR-3151 locus, we observed a significantly shorter OS (P=.05; log-rank test) in 
patients with high expression of BAALC, miR-3151 or both when compared to patients 














Even though the analyzed groups are very small, these data may give further support to 
the importance of the combined effect of the BAALC/miR-3151 locus. 
Figure 2: (A) OS according to BAALC expression, using the median cut to define high and low 
expressers treated at the University of Leipzig (n=22). (B) OS according to miR-3151 expression, using 
the median cut to define high and low expressers in AML patients treated at the University of Leipzig 
(n=22).  
Figure 3: OS according to BAALC 
and miR-3151expression, using the 
median cut to define high and low 
expressers for BAALC and miR-3151 
expression, treated at the University 
of Leipzig (n=22). Patients with either 
high BAALC or high miR-3151 
expression or both demonstrated 
worse OS compared to those 
patients with low BAALC and low 
miR-3151 expression (P=.05).  
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In conclusion, the here presented manuscript is not only the first report of the prognostic 
importance of a novel microRNA miR-3151, but it is the first example of an interaction 
between an intronic miR and its host gene in AML. Since so far the impact of intronic 
miRs on the effects of their host genes has been vastly overlooked, this discovery may 
initiate new research in the pathways of other human malignancies in which genes with 
intronic miRs are involved. In the case of BAALC and miR-3151, we may conclude that 
high expression of both oncogenes is important to promote leukemogenesis, since both 
are impacting on different downstream pathways and ultimately different outcome 
endpoints.  
Nothing is known about the downstream targets about BAALC yet, but since we could 
validate two members of the ubiquitination pathway as direct miR-3151 target genes, it 
may be tempting to speculate that BAALC may either also be involved in the 
ubiquitination pathway or that the repressed ubiquitination (and consecutive 
degradation) of the FBXL20 targets may directly or indirectly support the function of 
BAALC.  
The further characterization of the interplay of miR-3151 and its host gene BAALC may 
unravel novel pathways, which may lead to a better understanding of the pathogenesis 
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